Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
08 2022
Historique:
received: 18 04 2022
accepted: 09 06 2022
revised: 06 06 2022
pubmed: 28 6 2022
medline: 4 8 2022
entrez: 27 6 2022
Statut: ppublish

Résumé

Myeloperoxidase (MPO) gene alterations with variable clinical penetrance have been found in hereditary MPO deficiency, but their leukemia association in patients and carriers has not been established. Germline MPO alterations were found to be significantly enriched in myeloid neoplasms: 28 pathogenic/likely pathogenic variants were identified in 100 patients. The most common alterations were c.2031-2 A > C, R569W, M519fs* and Y173C accounting for about half of the cases. While functional experiments showed that the marrow stem cell pool of Mpo

Identifiants

pubmed: 35761024
doi: 10.1038/s41375-022-01630-0
pii: 10.1038/s41375-022-01630-0
doi:

Substances chimiques

Hydrogen Peroxide BBX060AN9V
Peroxidase EC 1.11.1.7

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2086-2096

Subventions

Organisme : NHLBI NIH HHS
ID : R35 HL135795
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL132071
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257544
Pays : United States

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Horwitz MS, Corey SJ, Grimes HL, Tidwell T. ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. Hematol Oncol Clin North Am. 2013;27:19–41.
pubmed: 23351986 doi: 10.1016/j.hoc.2012.10.004
Li ST, Wang J, Wei R, Shi R, Adema V, Nagata Y, et al. Rare germline variant contributions to myeloid malignancy susceptibility. Leukemia. 2020;34:1675–8.
pubmed: 31911633 pmcid: 8908771 doi: 10.1038/s41375-019-0701-8
Morishita K, Kubota N, Asano S, Kaziro Y, Nagata S. Molecular cloning and characterization of cDNA for human myeloperoxidase. J Biol Chem. 1987;262:3844–51.
pubmed: 3029127 doi: 10.1016/S0021-9258(18)61433-4
Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77:598–625.
pubmed: 15689384 doi: 10.1189/jlb.1204697
Nauseef WM. Myeloperoxidase in human neutrophil host defence. Cell Microbiol. 2014;16:1146–55.
pubmed: 24844117 pmcid: 4301731 doi: 10.1111/cmi.12312
Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519–31.
pubmed: 21785456 doi: 10.1038/nri3024
Pahwa R, Modi P, Jialal I Myeloperoxidase Deficiency. StatPearls. StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.: Treasure Island (FL), 2021.
Marchetti C, Patriarca P, Solero GP, Baralle FE, Romano M. Genetic studies on myeloperoxidase deficiency in Italy. Jpn J Infect Dis. 2004;57:S10–12.
pubmed: 15507752
Endo D, Saito T, Umeki Y, Suzuki K, Aratani Y. Myeloperoxidase negatively regulates the expression of proinflammatory cytokines and chemokines by zymosan-induced mouse neutrophils. Inflamm Res. 2016;65:151–9.
pubmed: 26573963 doi: 10.1007/s00011-015-0899-5
Milla C, Yang S, Cornfield DN, Brennan ML, Hazen SL, Panoskaltsis-Mortari A, et al. Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol. 2004;287:L706–714.
pubmed: 15020295 doi: 10.1152/ajplung.00015.2004
Kremserova S, Perecko T, Soucek K, Klinke A, Baldus S, Eiserich JP, et al. Lung Neutrophilia in Myeloperoxidase Deficient Mice during the Course of Acute Pulmonary Inflammation. Oxid Med Cell Longev. 2016;2016:5219056.
pubmed: 26998194 pmcid: 4779540 doi: 10.1155/2016/5219056
Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1102–11.
pubmed: 15790935 doi: 10.1161/01.ATV.0000163262.83456.6d
Strzepa A, Pritchard KA, Dittel BN. Myeloperoxidase: A new player in autoimmunity. Cell Immunol. 2017;317:1–8.
pubmed: 28511921 pmcid: 5665680 doi: 10.1016/j.cellimm.2017.05.002
Malle E, Buch T, Grone HJ. Myeloperoxidase in kidney disease. Kidney Int. 2003;64:1956–67.
pubmed: 14633118 doi: 10.1046/j.1523-1755.2003.00336.x
Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 2000;104:10–15.
pubmed: 11111115 doi: 10.1159/000041062
Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128:902–10.
pubmed: 27335276 pmcid: 5161006 doi: 10.1182/blood-2016-02-700054
Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45:942–6.
pubmed: 23832012 pmcid: 3729750 doi: 10.1038/ng.2696
Nagata Y, Makishima H, Kerr CM, Przychodzen BP, Aly M, Goyal A, et al. Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nat Commun. 2019;10:5386.
pubmed: 31772163 pmcid: 6879617 doi: 10.1038/s41467-019-13001-y
Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, et al. Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia. 2018;32:1751–61.
pubmed: 29795413 pmcid: 8673139 doi: 10.1038/s41375-018-0150-9
Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49:204–12.
pubmed: 27992414 doi: 10.1038/ng.3742
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.
pubmed: 20601685 pmcid: 2938201 doi: 10.1093/nar/gkq603
Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74:5463–7.
pubmed: 271968 pmcid: 431765 doi: 10.1073/pnas.74.12.5463
Nauseef WM, Cogley M, Bock S, Petrides PE. Pattern of inheritance in hereditary myeloperoxidase deficiency associated with the R569W missense mutation. J Leukoc Biol. 1998;63:264–9.
pubmed: 9468285 doi: 10.1002/jlb.63.2.264
DeLeo FR, Goedken M, McCormick SJ, Nauseef WM. A novel form of hereditary myeloperoxidase deficiency linked to endoplasmic reticulum/proteasome degradation. J Clin Invest. 1998;101:2900–9.
pubmed: 9637725 pmcid: 508882 doi: 10.1172/JCI2649
Romano M, Dri P, Da Dalt L, Patriarca P, Baralle FE. Biochemical and molecular characterization of hereditary myeloperoxidase deficiency. Blood. 1997;90:4126–34.
pubmed: 9354683 doi: 10.1182/blood.V90.10.4126
Lanza F, Fietta A, Spisani S, Castoldi GL, Traniello S. Does a relationship exist between neutrophil myeloperoxidase deficiency and the occurrence of neoplasms? J Clin Lab Immunol. 1987;22:175–80.
pubmed: 3039142
Cappelletti P, Lippi U. Hereditary myeloperoxidase deficiency: a rare condition? Diagnostic possibilities of a differential white cell autoanalyzer (Hemalog-D). Haematologica. 1983;68:736–41.
pubmed: 6321302
Lanza F. Clinical manifestation of myeloperoxidase deficiency. J Mol Med (Berl). 1998;76:676–81.
doi: 10.1007/s001090050267
Calado RT, Regal JA, Hills M, Yewdell WT, Dalmazzo LF, Zago MA, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA. 2009;106:1187–92.
pubmed: 19147845 pmcid: 2627806 doi: 10.1073/pnas.0807057106
Awan A, Malcolm Taylor G, Gokhale DA, Dearden SP. Increased Frequency of Fanconi Anemia Group C Genetic Variants in Children With Sporadic Acute Myeloid Leukemia. Blood. 1998;91:4813–4.
pubmed: 9616183 doi: 10.1182/blood.V91.12.4813
Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res. 2007;67:9591–6.
pubmed: 17909071 pmcid: 3622247 doi: 10.1158/0008-5472.CAN-07-1501
Rao S, Yao Y, Soares de Brito J, Yao Q, Shen AH, Watkinson RE, et al. Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell Stem Cell. 2021;28:833–45. 2021/05/06/e835
pubmed: 33513358 pmcid: 8106646 doi: 10.1016/j.stem.2020.12.015
Germeshausen M, Deerberg S, Peter Y, Reimer C, Kratz CP, Ballmaier M. The spectrum of ELANE mutations and their implications in severe congenital and cyclic neutropenia. Hum Mutat. 2013;34:905–14.
pubmed: 23463630 doi: 10.1002/humu.22308
Rydzynska Z, Pawlik B, Krzyzanowski D, Mlynarski W, Madzio J. Neutrophil Elastase Defects in Congenital Neutropenia. Front. Immunol. 2021;12:1–12.
Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, et al. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood. 2014;123:2229–37.
pubmed: 24523240 doi: 10.1182/blood-2013-11-538025
Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood. 2007;109:93–99.
pubmed: 16985178 doi: 10.1182/blood-2006-02-004275
Kettle AJ, Winterbourn CC. Myeloperoxidase: a key regulator of neutrophil oxidant production. Redox Rep. 1997;3:3–15.
pubmed: 27414766 doi: 10.1080/13510002.1997.11747085
Rosales C, Lowell CA, Schnoor M, Uribe-Querol E. Neutrophils: Their role in innate and adaptive immunity 2017. J Immunol Res. 2017;2017:9748345.
pubmed: 29238732 pmcid: 5697120 doi: 10.1155/2017/9748345
Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995;18:775–94.
pubmed: 7750801 doi: 10.1016/0891-5849(94)00198-S
Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem. 1997;272:217–21.
pubmed: 8995250 doi: 10.1074/jbc.272.1.217
Hansberg W, Aguirre J. Hyperoxidant states cause microbial cell differentiation by cell isolation from dioxygen. J Theor Biol. 1990;142:201–21.
pubmed: 2352433 doi: 10.1016/S0022-5193(05)80222-X
Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA. 2001;98:5550–5.
pubmed: 11331784 pmcid: 33250 doi: 10.1073/pnas.101505898
Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today. 1994;15:7–10.
pubmed: 8136014 doi: 10.1016/0167-5699(94)90018-3
Forman HJ, Bernardo A, Davies KJ. What is the concentration of hydrogen peroxide in blood and plasma? Arch Biochem Biophys. 2016;603:48–53.
pubmed: 27173735 doi: 10.1016/j.abb.2016.05.005
Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. Redox Biol. 2017;11:613–9.
pubmed: 28110218 pmcid: 5256672 doi: 10.1016/j.redox.2016.12.035
Valverde M, Lozano-Salgado J, Fortini P, Rodriguez-Sastre MA, Rojas E, Dogliotti E. Hydrogen Peroxide-Induced DNA Damage and Repair through the Differentiation of Human Adipose-Derived Mesenchymal Stem Cells. Stem Cells Int. 2018;2018:1615497.
pubmed: 30405718 pmcid: 6199883 doi: 10.1155/2018/1615497
Driessens N, Versteyhe S, Ghaddhab C, Burniat A, De Deken X, Van Sande J, et al. Hydrogen peroxide induces DNA single- and double-strand breaks in thyroid cells and is therefore a potential mutagen for this organ. Endocr Relat Cancer. 2009;16:845–56.
pubmed: 19509065 doi: 10.1677/ERC-09-0020
McDonald RJ, Pan LC, St George JA, Hyde DM, Ducore JM. Hydrogen peroxide induces DNA single strand breaks in respiratory epithelial cells. Inflammation. 1993;17:715–22.
pubmed: 8112830 doi: 10.1007/BF00920476

Auteurs

Sunisa Kongkiatkamon (S)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Research Unit in Translational Hematology, Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Laila Terkawi (L)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Yihong Guan (Y)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Vera Adema (V)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Metis Hasipek (M)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Tatiana Dombrovski (T)

Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.

Milo Co (M)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Wencke Walter (W)

MLL Munich Leukemia Laboratory, Munich, Germany.

Hassan Awada (H)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Yvonne Parker (Y)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Stephan Hutter (S)

MLL Munich Leukemia Laboratory, Munich, Germany.

Simona Pagliuca (S)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Carmelo Gurnari (C)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Heesun J Rogers (HJ)

Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.

Manja Meggendorfer (M)

MLL Munich Leukemia Laboratory, Munich, Germany.

Daniel J Lindner (DJ)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Torsten Haferlach (T)

MLL Munich Leukemia Laboratory, Munich, Germany.

Valeria Visconte (V)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Thomas LaFramboise (T)

Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.

Babal K Jha (BK)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Jaroslaw P Maciejewski (JP)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH